Angiopoietin-2 Interferes with Anti-VEGFR2–Induced Vessel Normalization and Survival Benefit in Mice Bearing Gliomas
Open accessPublished version of a preprint
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Purpose: In brain tumors, cerebral edema is a significant source of morbidity and mortality. Recent studies have shown that inhibition of vascular endothelial growth factor (VEGF) signaling induces transient vascular normalization and reduces cerebral edema, resulting in a modest survival benefit in glioblastoma patients. During anti-VEGF treatment, circulating levels of angiopoietin (Ang)-2 remained high after an initial minor reduction. It is not known, however, whether Ang-2 can modulate anti-VEGF treatment of glioblastoma. Here, we used an orthotopic glioma model to test the hypothesis that Ang-2 is an additional target for improving the efficacy of current anti-VEGF therapies in glioma patients. Experimental Design: To recapitulate high levels of Ang-2 in glioblastoma patients during anti-VEGF treatment, Ang-2 was ectopically expressed in U87 glioma cells. Animal survival and tumor growth were assessed to determine the effects of Ang-2 and anti–VEGF receptor 2 (VEGFR2) treatment. We also monitored morphologic and functional vascular changes using multiphoton laser scanning microscopy and immunohistochemistry. Results: Ectopic expression of Ang-2 had no effect on vascular permeability, tumor growth, or survival, although it resulted in higher vascular density, with dilated vessels and reduced mural cell coverage. On the other hand, when combined with anti-VEGFR2 treatment, Ang-2 destabilized vessels without affecting vessel regression and compromised the survival benefit of VEGFR2 inhibition by increasing vascular permeability. VEGFR2 inhibition normalized tumor vasculature whereas ectopic expression of Ang-2 diminished the beneficial effects of VEGFR2 blockade by inhibiting vessel normalization. Conclusion: Cancer treatment regimens combining anti-VEGF and anti-Ang-2 agents may be an effective strategy to improve the efficacy of current anti-VEGF therapies. Clin Cancer Res; 16(14); 3618–27. ©2010 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ectopic expression of ANG2 can abrogate the benefit of anti-VEGF therapy66.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [66]
In the citing paper
“overexpression of ANG2 can compromise the benefit of VEGF pathway inhibition by abrogating vessel normalization66”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [66]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Batchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W.-T., Duda, D. G., Cohen, K. S., Kozak, K. R., Cahill, D. P., Chen, P.-J., Zhu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.021 · Cited by 1,769
Self-citationControl of vascular morphogenesis and homeostasis through the angiopoietin–Tie system
Augustin, H. G., Young Koh, G., Thurston, G., & Alitalo, K. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2639 · Cited by 1,465
Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E., & Hanahan, D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17929 · Cited by 1,370
Bergers, G., Song, S., Meyer-Morse, N., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317929 · Cited by 1,192
Vascular permeability factor (VPF, VEGF) in tumor biology
Senger, D. R., Van De Water, L., Brown, L. F., Nagy, J. A., Yeo, K.-T., Yeo, T.-K., Berse, B., Jackman, R. W., Dvorak, A. M., & Dvorak, H. F. (1993) · Cancer and Metastasis Reviews · doi:10.1007/bf00665960 · Cited by 840
Erber, R., Thurnher, A., D. Katsen, A., Groth, G., Kerger, H., Hammes, H., D. Menger, M., Ullrich, A., & Vajkoczy, P. (2004) · The FASEB Journal · doi:10.1096/fj.03-0271fje · Cited by 610
Biomarkers of response and resistance to antiangiogenic therapy
Jain, R. K., Duda, D. G., Willett, C. G., Sahani, D. V., Zhu, A. X., Loeffler, J. S., Batchelor, T. T., & Sorensen, A. G. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.63 · Cited by 572
Self-citationBatchelor, T. T., Duda, D. G., di Tomaso, E., Ancukiewicz, M., Plotkin, S. R., Gerstner, E., Eichler, A. F., Drappatz, J., Hochberg, F. H., Benner, T., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3988 · Cited by 520 · cited 3×
“er Res; 16(14) July 15, 2010 toma patients (6), whereas high Ang-2 levels correlate with resistance to anti-VEGF therapy (6).”
BackgroundSelf-citationShojaei, F., Wu, X., Qu, X., Kowanetz, M., Yu, L., Tan, M., Meng, Y. G., & Ferrara, N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902280106 · Cited by 471
Willett, C. G., Boucher, Y., Duda, D. G., di Tomaso, E., Munn, L. L., Tong, R. T., Kozin, S. V., Petit, L., Jain, R. K., Chung, D. C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.5635 · Cited by 420
Self-citation
Cited by
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Self-citationTumor angiogenesis: causes, consequences, challenges and opportunities
Lugano, R., Ramachandran, M., & Dimberg, A. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03351-7 · Cited by 1,986
Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases
Carmeliet, P., & Jain, R. K. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3455 · Cited by 1,675
Self-citationNormalization of the Vasculature for Treatment of Cancer and Other Diseases
Goel, S., Duda, D. G., Xu, L., Munn, L. L., Boucher, Y., Fukumura, D., & Jain, R. K. (2011) · Physiological Reviews · doi:10.1152/physrev.00038.2010 · Cited by 1,605
“In contrast, a recent report has documented intratumoral hypoxia in rodents bearing GBM treated with bevacizumab, but this study only examined tumors at later timepoints and did not explore temporal kinetics of such changes (166).”
InfluentialSelf-citationFagiani, E., & Christofori, G. (2013) · Cancer Letters · doi:10.1016/j.canlet.2012.08.018 · Cited by 676
Metadata
- Authors
- Chae, S.-S., Kamoun, W. S., Farrar, C. T., Kirkpatrick, N. D., Niemeyer, E., de Graaf, A. M. A., Sorensen, A. G., Munn, L. L., Jain, R. K., & Fukumura, D.
- Affiliations
- Harvard University (US)
- Authors' Affiliations: 1Edwin L. Steele Laboratory, Department of Radiation Oncology, and 2Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts; and 3UK-SH Campus Luebeck, Klinik für Strahlentherapie, Universitaet zu Luebeck, Germany
- Corresponding author
- Jain, Rakesh K.
- Fukumura, Dai
- Venue
- Clinical Cancer Research
- Published
- 2010-07-14
- Volume
- 16
- Issue
- 14
- Pages
- 3618-3627
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC2905497
- OpenAlex
- W2166215138
- Cited by
- 135
- References
- 29
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 5 · 2023: 16 · 2022: 9 · 2021: 8 · 2020: 5 · 2019: 5 · 2018: 5 · 2017: 7 · 2016: 14 · 2015: 11 · 2014: 7 · 2013: 10 · 2012: 8
- FWCI
- 4.53
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Institute on Aging (K25AG029415)
- National Cancer Institute (R01CA115767, T32CA073479, R01CA085140, R01CA096915, P01CA080124, R01CA126642)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- angiopoietin-2, VEGFR-2 inhibition, anti-VEGF therapy, glioblastoma, tumor vasculature normalization, cerebral edema, vascular permeability, tumor vasculature, combination therapy, orthotopic glioma model, U87 cells
- MeSH terms
- Animals, Cell Survival, Disease Models, Animal, Glioma, Humans, Immunohistochemistry, Neoplasm Transplantation, Neovascularization, Pathologic, Reverse Transcriptase Polymerase Chain Reaction, Xenograft Model Antitumor Assays, Vascular Endothelial Growth Factor Receptor-2, Angiopoietin-2, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Angiopoietin-2 Interferes with Anti-VEGFR2–Induced Vessel Normalization and Survival Benefit in Mice Bearing Gliomas. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-09-3073
- The paper
- Chae, S.-S., Kamoun, W. S., Farrar, C. T., Kirkpatrick, N. D., Niemeyer, E., de Graaf, A. M. A., Sorensen, A. G., Munn, L. L., Jain, R. K., & Fukumura, D. (2010). Angiopoietin-2 Interferes with Anti-VEGFR2–Induced Vessel Normalization and Survival Benefit in Mice Bearing Gliomas. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-09-3073
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.